Department of Hematology, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 9601295, Japan.
Department of Diagnostic Pathology, Fukushima Medical University, Fukushima, Japan.
Int J Hematol. 2021 Dec;114(6):639-652. doi: 10.1007/s12185-021-03211-w. Epub 2021 Aug 30.
The diagnosis of plasmablastic lymphoma (PBL), plasmablastic myeloma (PBM), and plasmablastic neoplasm (PBN) may be arbitrary in some cases because these entities can be indistinct. We conducted this scoping review to investigate heterogeneity in diagnostic criteria used in previous studies and validate the diagnostic results of previous diagnostic algorithms and the algorithm we developed, which also includes diagnosis of PBN. Using the PRISMA Extension for Scoping Reviews, we analyzed literature published between September 2017 and April 2020. We identified a total of 163 cases (128 PBL, 32 PBM, and 3 PBN) from 77 case reports and 8 case series. We found that diagnostic criteria in the literature varied for PBL but were consistent for PBM. Our algorithm was the first attempt to include PBN in a complete structure. The results of the three diagnostic algorithms varied significantly. Hematologists and pathologists should pay more attention to the differential diagnosis of PBL, PBM, and PBN.
浆细胞样淋巴瘤（PBL）、浆母细胞骨髓瘤（PBM）和浆母细胞肿瘤（PBN）的诊断在某些情况下可能具有随意性，因为这些实体之间可能没有明显区别。我们进行了这项范围界定综述，以调查既往研究中使用的诊断标准的异质性，并验证我们开发的诊断算法和既往诊断算法的诊断结果，该算法还包括 PBN 的诊断。我们使用 PRISMA 扩展范围界定综述方法，分析了 2017 年 9 月至 2020 年 4 月期间发表的文献。我们从 77 份病例报告和 8 个病例系列中总共确定了 163 例病例（128 例 PBL、32 例 PBM 和 3 例 PBN）。我们发现文献中的诊断标准在 PBL 方面存在差异，但在 PBM 方面是一致的。我们的算法首次尝试将 PBN 纳入完整的结构。这三种诊断算法的结果差异显著。血液学家和病理学家应更加注意 PBL、PBM 和 PBN 的鉴别诊断。
